MISGAV, Israel & LONDON--(BUSINESS WIRE)--Medgenics (AIM:MEDU) (AIM:MEDG), today announces that the EPODURE Biopump, the Company’s unique tissue-based technology, has successfully demonstrated safety and efficacy for the sustained protein therapy of anemia in patients with chronic kidney disease (CKD).
